What is the appropriate aspirin dosing regimen for Kawasaki disease during the acute febrile phase and the subsequent convalescent phase?

Aspirin Dosing in Kawasaki Disease

For acute Kawasaki disease, administer aspirin at 80-100 mg/kg/day divided into 4 doses during the febrile phase, then transition to low-dose aspirin (3-5 mg/kg/day) once the child has been afebrile for 48-72 hours, continuing until 6-8 weeks after illness onset if no coronary abnormalities develop. 1

Acute Phase Dosing (Febrile Period)

The American Heart Association guidelines establish 80-100 mg/kg/day divided into 4 doses as the standard high-dose regimen during acute illness 1. This high dose provides anti-inflammatory effects that work additively with IVIG, though importantly, aspirin does not independently reduce coronary artery abnormality rates 1.

Timing of dose reduction: Two acceptable approaches exist:

• Reduce after 48-72 hours of being afebrile (most common practice) 1
• Continue until day 14 of illness AND 48-72 hours after fever cessation 1

The 2012 ACCP guidelines provide a Grade 1B recommendation for this high-dose approach (up to 14 days), reflecting strong evidence 2.

Convalescent Phase Dosing

Transition to 3-5 mg/kg/day as a single daily dose for antiplatelet effects 1. Continue this regimen:

• Until 6-8 weeks after illness onset if echocardiography shows no coronary changes 1
• Indefinitely if coronary abnormalities develop 1

Special Considerations for Coronary Involvement

For children with coronary aneurysms:

• Small aneurysms: Continue low-dose aspirin indefinitely 3
• Moderate aneurysms (4-6 mm): Consider adding clopidogrel to aspirin 3
• Giant aneurysms (≥8 mm): Add warfarin (INR 2.0-3.0) to low-dose aspirin 3

Critical Safety Issues

Reye syndrome risk: Children on aspirin therapy face increased risk with influenza or varicella infection 1, 4. Mandate:

• Annual inactivated influenza vaccine for all children on long-term aspirin 1, 4
• Consider substituting alternative antiplatelet agents during active viral infections 1, 4
• For varicella vaccine, weigh theoretical risks against wild-type varicella exposure 1

Ibuprofen antagonism: Avoid ibuprofen in children with coronary aneurysms taking aspirin, as it antagonizes irreversible platelet inhibition (evidence level B) 1.

Emerging Evidence on Dosing Controversy

Recent data challenges the necessity of high-dose aspirin. A 2024 Japanese nationwide study of 82,109 patients found no significant association between aspirin doses ≥30 mg/kg/day and coronary artery abnormalities 5. The 2017 AHA statement acknowledges both 80-100 mg/kg/day (US practice) and 30-50 mg/kg/day (Japanese/European practice) as acceptable options 4. A 2026 retrospective study showed similar outcomes with low-dose aspirin plus IVIG compared to high-dose regimens 6.

However, established guidelines still recommend the high-dose approach 1, 2, and this remains the standard of care in the United States. The high-dose regimen carries minimal additional risk when properly monitored and transitioned appropriately.

Practical Algorithm

1. Diagnosis confirmed → Start 80-100 mg/kg/day divided q6h + IVIG 2 g/kg
2. Afebrile for 48-72 hours → Reduce to 3-5 mg/kg/day once daily
3. Echo at 6-8 weeks:
   • No coronary changes → Discontinue aspirin
   • Coronary abnormalities present → Continue indefinitely, consider additional anticoagulation based on severity
4. Monitor for: Influenza/varicella exposure, bleeding complications, salicylate toxicity